GlassScriptPhysician profile
Laurie M Allen
NPI 1801093794
$10,700.28
in general payments reported to CMS, 2019-2025
36 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $238 · 2021: $7,614 · 2022: $622 · 2023: $718 · 2024: $455 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,014.16 | 2021-2024 | |
| Abbvie INC. | $756.58 | 2019-2024 | Liletta, Orilissa, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $472.31 | 2021-2025 | |
| Minerva Surgical, INC | $306.02 | 2019-2023 | |
| Daiichi Sankyo INC. | $223.95 | 2020-2023 | Injectafer |
| Sumitomo Pharma America, INC. | $206.57 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $197.67 | 2019-2025 | |
| Myovant Sciences INC. | $165.33 | 2021-2022 | |
| Astellas Pharma US INC | $134.34 | 2024-2025 | Veozah |
| Organon LLC | $130.18 | 2021-2025 | Nexplanon |
| Alexion Pharmaceuticals, INC. | $125.00 | 2019 | |
| Hologic Sales and Service, LLC | $122.74 | 2019-2025 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Exeltis, USA INC. | $113.89 | 2021-2025 | Slynd |
| Therapeuticsmd, INC. | $92.75 | 2019 | |
| Celgene Corporation | $65.87 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $53.29 | 2022-2024 | Paragard T 380a, Paragard T 380a |
| Biogen, INC. | $48.32 | 2025 | Zurzuvae |
| Axonics, INC. | $46.78 | 2022-2023 | Bulkamid, Axonics |
| Myriad Women'S Health, INC. | $41.48 | 2023 | Myrisk |
| Agile Therapeutics, INC. | $39.12 | 2021 | |
| Ethicon US, LLC | $36.86 | 2019-2021 | |
| Shield Therapeutics INC | $33.29 | 2022-2023 | Accrufer |
| Boston Scientific Corporation | $31.42 | 2024 | Lux-Dx Insertable Cardiac Monitor |
| Millicent US INC | $31.25 | 2021-2025 | Femring, Intrarosa |
| Pacira Pharmaceuticals Incorporated | $24.90 | 2022 | |
| Aspira Women'S Health INC | $22.00 | 2024 | Ova1 |
| Roche Diagnostics Corporation | $21.71 | 2019 | |
| Becton, Dickinson and Company | $19.66 | 2023 | Bd Max System, Bd Max Instrument |
| Merck Sharp & Dohme LLC | $18.95 | 2022 | |
| Gynesonics, INC. | $18.41 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Channel Medsystems, INC. | $16.64 | 2022 | |
| United Therapeutics Corporation | $16.03 | 2021 | |
| Evofem Biosciences, INC. | $15.10 | 2021 | |
| Pfizer INC. | $13.10 | 2024 | |
| Radius Health, INC. | $12.34 | 2020 | |
| Covidien LP | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurie Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.